Marinos C Dalakas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/990663/publications.pdf Version: 2024-02-01

219 papers	22,136 citations	7568 77 h-index	9345 143 g-index
224	224	224	12443
all docs	docs citations	times ranked	citing authors

#	Article	lF	CITATIONS
1	Autoimmune Neurogenic Dysphagia. Dysphagia, 2022, 37, 473-487.	1.8	9
2	Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data. Neurological Sciences, 2022, 43, 2641-2649.	1.9	6
3	Unconvincing Evidence of SARS-CoV-2–Associated Myositis in Autopsied Muscles. JAMA Neurology, 2022, 79, 92.	9.0	3
4	lgG4-Mediated Neurologic Autoimmunities. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	45
5	Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies. Neurotherapeutics, 2022, 19, 832-847.	4.4	33
6	Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases. Neurotherapeutics, 2022, 19, 691-710.	4.4	21
7	Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	103
8	Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies. Neurotherapeutics, 2022, 19, 741-752.	4.4	16
9	Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits. Expert Review of Clinical Immunology, 2022, 18, 413-423.	3.0	17
10	Progressive multifocal fibrosing neuropathy: description of a novel disease. Acta Neuropathologica Communications, 2022, 10, 34.	5.2	0
11	Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis. Expert Review of Neurotherapeutics, 2022, 22, 313-318.	2.8	2
12	The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies. Neurotherapeutics, 2022, 19, 864-873.	4.4	16
13	Natalizumab therapy in patients with pediatric-onset multiple sclerosis in Greece: clinical and immunological insights of time-long administration and future directions—a single-center retrospective observational study. Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395, 933-943.	3.0	3
14	Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Review of Clinical Immunology, 2022, 18, 691-701.	3.0	25
15	Therapeutic Antibodies in Neurological Diseases: Witnessing the Continuation of the Impressive Success in Neuro-Immunotherapies. Neurotherapeutics, 2022, 19, 687-690.	4.4	1
16	Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody–Positive Stiff-Person Syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	13
17	Limited Benefits Halt Enrollment in Hematopoietic Stem Cell Transplantation Trial for Stiff-Person Syndrome. Neurology, 2021, 96, 239-240.	1.1	8
18	LGI1 encephalitis with squamous lung-cell carcinoma: Resolution after tumor resection. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	1

#	Article	IF	CITATIONS
19	GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110034.	3.5	39
20	Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications. Frontiers in Immunology, 2021, 12, 627285.	4.8	37
21	Aggressive Herpes Zoster in Young Patients With Multiple Sclerosis Under Dimethyl Fumarate. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	4
22	The importance of FcRn in neuro-immunotherapies: From IgG catabolism, <i>FCGRT</i> gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199738.	3.5	50
23	N2 year in review. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e925.	6.0	3
24	Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy. Neurotherapeutics, 2021, 18, 2397-2418.	4.4	36
25	Anti-Neuronal Antibodies Within the IVIg Preparations: Importance in Clinical Practice. Neurotherapeutics, 2020, 17, 235-242.	4.4	18
26	Complement in neurological disorders and emerging complement-targeted therapeutics. Nature Reviews Neurology, 2020, 16, 601-617.	10.1	163
27	Anti–SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	110
28	Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies. Current Opinion in Neurology, 2020, 33, 545-552.	3.6	40
29	Anti-SARS-CoV-2 antibody detection in healthcare workers of two tertiary hospitals in Athens, Greece. Clinical Immunology, 2020, 221, 108619.	3.2	12
30	Cranial neuropathies and COVID-19. Neurology, 2020, 95, 195-196.	1.1	86
31	Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	201
32	N2 year in review. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e644.	6.0	1
33	Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications. Acta Myologica, 2020, 39, 289-301.	1.5	25
34	Autoimmune Peripheral Neuropathies. , 2019, , 903-915.e1.		1
35	Trial of canakinumab, an IL- $1^{\hat{l}_2}$ receptor antagonist, in patients with inclusion body myositis. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e581.	6.0	17
36	The immunobiology of autoimmune encephalitides. Journal of Autoimmunity, 2019, 104, 102339.	6.5	44

#	Article	IF	CITATIONS
37	Case 22-2019: A 65-Year-Old Woman with Myopathy. New England Journal of Medicine, 2019, 381, 1693-1694.	27.0	6
38	Treatment of Stiff-Person Syndrome. Current Clinical Neurology, 2019, , 333-335.	0.2	2
39	IVIG efficacy in CIDP patients is not associated with terminal complement inhibition. Journal of Neuroimmunology, 2019, 330, 23-27.	2.3	11
40	Immunotherapy in myasthenia gravis in the era of biologics. Nature Reviews Neurology, 2019, 15, 113-124.	10.1	123
41	Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder. BMC Neurology, 2019, 19, 1.	1.8	112
42	Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e460.	6.0	20
43	Are autoantibodies pathogenic in necrotizing myopathy?. Nature Reviews Rheumatology, 2018, 14, 251-252.	8.0	22
44	Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAC antibody-mediated neuropathies. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628561774664.	3.5	69
45	Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy. Lancet Neurology, The, 2018, 17, 20-21.	10.2	5
46	Neurological complications of immune checkpoint inhibitors: what happens when you â€~take the brakes off' the immune system. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879986.	3.5	136
47	Postherpes simplex encephalitis: a case series of viral-triggered autoimmunity, synaptic autoantibodies and response to therapy. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641876877.	3.5	33
48	Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. Lancet Neurology, The, 2018, 17, 689-698.	10.2	48
49	Use of Intravenous Immunoglobulin in Neurology. , 2018, , 101-109.		2
50	Antibodies to inositol 1,4,5-triphosphate receptor 1 in patients with cerebellar disease. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e306.	6.0	9
51	Rituximab in anti-MAG neuropathy: More evidence for efficacy and more predictive factors. Journal of the Neurological Sciences, 2017, 377, 224-226.	0.6	12
52	A doubleâ€blind, placebo ontrolled study of rituximab in patients with stiff person syndrome. Annals of Neurology, 2017, 82, 271-277.	5.3	78
53	Gene therapy for Duchenne muscular dystrophy: balancing good science, marginal efficacy, high emotions and excessive cost. Therapeutic Advances in Neurological Disorders, 2017, 10, 293-296.	3.5	15
54	Necrotising autoimmune myopathy (NAM): antibodies seem to be specific markers in aiding diagnosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1037-1037.	1.9	18

#	Article	IF	CITATIONS
55	Treating myasthenia on consensus guide: Helpful and challenging but still unfinished business. Neurology, 2016, 87, 350-351.	1.1	6
56	Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM. BMC Neurology, 2016, 16, 48.	1.8	18
57	Close to the node but far enough. Neurology, 2016, 86, 796-797.	1.1	7
58	Viruses in IBM. Neurology, 2016, 86, 204-205.	1.1	8
59	Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future. Neurotherapeutics, 2016, 13, 1-3.	4.4	7
60	Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials. Neurotherapeutics, 2016, 13, 20-33.	4.4	25
61	Efficacy of Intravenous Immunoglobulin in Neurological Diseases. Neurotherapeutics, 2016, 13, 34-46.	4.4	66
62	Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity. Neurotherapeutics, 2016, 13, 163-178.	4.4	17
63	Progressive encephalomyelitis with rigidity and myoclonus (PERM): brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab. Therapeutic Advances in Neurological Disorders, 2016, 9, 69-73.	3.5	13
64	Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e131.	6.0	98
65	Future perspectives in target-specific immunotherapies of myasthenia gravis. Therapeutic Advances in Neurological Disorders, 2015, 8, 316-327.	3.5	32
66	Intravenous immunoglobulin in neurology—mode of action and clinical efficacy. Nature Reviews Neurology, 2015, 11, 80-89.	10.1	228
67	Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders. Nature Reviews Neurology, 2015, 11, 143-156.	10.1	91
68	Inflammatory Muscle Diseases. New England Journal of Medicine, 2015, 373, 393-394.	27.0	145
69	HMGB1 and RAGE in skeletal muscle inflammation: Implications for protein accumulation in inclusion body myositis. Experimental Neurology, 2015, 271, 189-197.	4.1	32
70	Inflammatory Muscle Diseases. New England Journal of Medicine, 2015, 372, 1734-1747.	27.0	559
71	GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders. Journal of Neuroimmunology, 2015, 281, 73-77.	2.3	42
72	Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease. Journal of Neuroimmunology, 2015, 289, 8-11.	2.3	30

#	Article	IF	CITATIONS
73	Reliability of the Adult Myopathy Assessment Tool in Individuals With Myositis. Arthritis Care and Research, 2015, 67, 563-570.	3.4	9
74	Pathogenesis of immune-mediated neuropathies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 658-666.	3.8	92
75	Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. Journal of Clinical Investigation, 2015, 125, 4160-4170.	8.2	229
76	Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4. Autoimmunity, 2015, 48, 453-9.	2.6	6
77	Autoimmune encephalitis with GABA _B antibodies, thymoma, and GABA _B receptor thymic expression. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e39.	6.0	25
78	Reduction of Intraepidermal Nerve Fiber Density (IENFD) in the skin biopsies of patients with fibromyalgia: A controlled study. Journal of the Neurological Sciences, 2014, 347, 143-147.	0.6	76
79	Mechanistic Effects of IVIg in Neuroinflammatory Diseases: Conclusions Based on Clinicopathologic Correlations. Journal of Clinical Immunology, 2014, 34, 120-126.	3.8	38
80	IVIg in the chronic management of myasthenia gravis: Is it enough for your money?. Journal of the Neurological Sciences, 2014, 338, 1-2.	0.6	7
81	Immunotherapy-responsive limbic encephalitis with antibodies to glutamic acid decarboxylase. Journal of the Neurological Sciences, 2014, 343, 192-194.	0.6	22
82	Pathophysiology of autoimmune polyneuropathies. Presse Medicale, 2013, 42, e181-e192.	1.9	25
83	Immunology of stiff person syndrome and other GAD-associated neurological disorders. Expert Review of Clinical Immunology, 2013, 9, 1043-1053.	3.0	57
84	Progress and stiff challenges in understanding the role of GAD-antibodies in stiff-person syndrome. Experimental Neurology, 2013, 247, 303-307.	4.1	28
85	The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): A small pilot study. Journal of the Neurological Sciences, 2013, 334, 123-125.	0.6	51
86	Novel future therapeutic options in Myasthenia Gravis. Autoimmunity Reviews, 2013, 12, 936-941.	5.8	39
87	Glycine receptor antibodies in stiff-person syndrome and other GAD-positive CNS disorders. Neurology, 2013, 81, 1962-1964.	1.1	49
88	Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives. Expert Review of Clinical Immunology, 2013, 9, 1125-1133.	3.0	27
89	Incidence and Prevalence of Major Central Nervous System Involvement in Systemic Lupus Erythematosus: A 3-Year Prospective Study of 370 Patients. PLoS ONE, 2013, 8, e55843.	2.5	83

90 Autoimmune peripheral neuropathies. , 2013, , 801-811.

#	Article	IF	CITATIONS
91	Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1β-induced accumulation of β-amyloid and cell death. Brain, 2012, 135, 1102-1114.	7.6	58
92	Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: Quantitative assessment of inflammation and βâ€amyloid in the muscle. Arthritis and Rheumatism, 2012, 64, 4094-4103.	6.7	25
93	Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future. Annals of the New York Academy of Sciences, 2012, 1274, 1-8.	3.8	17
94	Pathogenesis and therapies of immune-mediated myopathies. Autoimmunity Reviews, 2012, 11, 203-206.	5.8	90
95	Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies. Journal of the Peripheral Nervous System, 2012, 17, 34-39.	3.1	26
96	Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. Journal of Clinical Investigation, 2012, 122, 1393-1402.	8.2	55
97	Advances in the diagnosis, pathogenesis and treatment of CIDP. Nature Reviews Neurology, 2011, 7, 507-517.	10.1	218
98	Peripheral neuropathies in Sjogren syndrome: a new reappraisal. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 798-802.	1.9	73
99	Pathophysiology of inflammatory and autoimmune myopathies. Presse Medicale, 2011, 40, e237-e247.	1.9	68
100	Inflammatory myopathies. Current Opinion in Neurology, 2011, 24, 457-462.	3.6	40
101	Potential biomarkers for monitoring therapeutic response in patients with CIDP. Journal of the Peripheral Nervous System, 2011, 16, 63-67.	3.1	21
102	Paraneoplastic anti-NMDAR encephalitis: long term follow-up reveals persistent serum antibodies. Journal of Neurology, 2011, 258, 1568-1570.	3.6	36
103	Immunotherapy of Inflammatory Myopathies: Practical Approach and Future Prospects. Current Treatment Options in Neurology, 2011, 13, 311-323.	1.8	46
104	Practical considerations on the use of rituximab in autoimmune neurological disorders. Therapeutic Advances in Neurological Disorders, 2010, 3, 93-105.	3.5	74
105	Pathogenesis and Treatment of Anti-MAG Neuropathy. Current Treatment Options in Neurology, 2010, 12, 71-83.	1.8	62
106	Electrophysiologic correlations with clinical outcomes in CIDP. Muscle and Nerve, 2010, 42, 492-497.	2.2	56
107	A critical update on the immunopathogenesis of Stiff Person Syndrome. European Journal of Clinical Investigation, 2010, 40, 1018-1025.	3.4	60
108	Inclusion-body myositis in the elderly: an update. Aging Health, 2010, 6, 687-694.	0.3	8

#	Article	IF	CITATIONS
109	Inflammatory myopathies. , 2010, , 427-452.		9
110	Timing and Course of Clinical Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Archives of Neurology, 2010, 67, 802.	4.5	99
111	Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Current Opinion in Pharmacology, 2010, 10, 346-352.	3.5	97
112	Immunotherapy of myositis: issues, concerns and future prospects. Nature Reviews Rheumatology, 2010, 6, 129-137.	8.0	151
113	Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies. Expert Opinion on Medical Diagnostics, 2010, 4, 241-250.	1.6	23
114	Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain, 2009, 132, 1536-1544.	7.6	182
115	Placeboâ€controlled trial of rituximab in IgM anti–myelinâ€associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology, 2009, 65, 286-293.	5.3	274
116	Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle and Nerve, 2009, 39, 448-455.	2.2	42
117	Stiff person syndrome: Advances in pathogenesis and therapeutic interventions. Current Treatment Options in Neurology, 2009, 11, 102-110.	1.8	164
118	Tragedy in a heartbeat: malfunctioning desmin causes skeletal and cardiac muscle disease. Journal of Clinical Investigation, 2009, 119, 1806-1813.	8.2	237
119	Advances in the pathogenesis and treatment of patients with stiff person syndrome. Current Neurology and Neuroscience Reports, 2008, 8, 48-55.	4.2	46
120	IVIg in other autoimmune neurological disorders: current status and future prospects. Journal of Neurology, 2008, 255, 12-16.	3.6	52
121	Interplay between inflammation and degeneration: Using inclusion body myositis to study "neuroinflammation― Annals of Neurology, 2008, 64, 1-3.	5.3	55
122	B cells as therapeutic targets in autoimmune neurological disorders. Nature Clinical Practice Neurology, 2008, 4, 557-567.	2.5	162
123	Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurology, The, 2008, 7, 136-144.	10.2	582
124	Autoimmune peripheral neuropathies. , 2008, , 977-994.		4
125	High definition profiling of autoantibodies to glutamic acid decarboxylases GAD65/GAD67 in stiff-person syndrome. Biochemical and Biophysical Research Communications, 2008, 366, 1-7.	2.1	45
126	Invited Article: Inhibition of B cell functions. Neurology, 2008, 70, 2252-2260.	1.1	95

#	Article	IF	CITATIONS
127	Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle. Brain, 2008, 131, 1228-1240.	7.6	184
128	Review: Therapeutic advances and future prospects in immune-mediated inflammatory myopathies. Therapeutic Advances in Neurological Disorders, 2008, 1, 157-166.	3.5	13
129	Drug Insight: the use of intravenous immunoglobulin in neurology—therapeutic considerations and practical issues. Nature Clinical Practice Neurology, 2007, 3, 36-44.	2.5	121
130	Inclusion body myositis with human immunodeficiency virus infection: Four cases with clonal expansion of viral-specific T cells. Annals of Neurology, 2007, 61, 466-475.	5.3	79
131	β-Amyloid is a substrate of autophagy in sporadic inclusion body myositis. Annals of Neurology, 2007, 61, 476-483.	5.3	126
132	Terminal latency index in neuropathy with antibodies against myelinâ€associated glycoproteins. Muscle and Nerve, 2007, 35, 196-202.	2.2	45
133	Therapeutic targets in patients with inflammatory myopathies: Present approaches and a look to the future. Neuromuscular Disorders, 2006, 16, 223-236.	0.6	59
134	B cells in the pathophysiology of autoimmune neurological disorders: A credible therapeutic target. , 2006, 112, 57-70.		40
135	Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain, 2006, 129, 3270-3276.	7.6	116
136	Sporadic inclusion body myositis—diagnosis, pathogenesis and therapeutic strategies. Nature Clinical Practice Neurology, 2006, 2, 437-447.	2.5	192
137	Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology, 2006, 67, 1068-1070.	1.1	95
138	Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology, 2006, 66, S33-S38.	1.1	93
139	Mechanisms of Disease: signaling pathways and immunobiology of inflammatory myopathies. Nature Clinical Practice Rheumatology, 2006, 2, 219-227.	3.2	101
140	Brain Î ³ -Aminobutyric Acid Changes in Stiff-Person Syndrome. Archives of Neurology, 2005, 62, 970-4.	4.5	75
141	Intravenous Immunoglobulin in Patients With Anti-GAD Antibody-Associated Neurological Diseases and Patients With Inflammatory Myopathies: Effects on Clinicopathological Features and Immunoregulatory Genes. Clinical Reviews in Allergy and Immunology, 2005, 29, 255-270.	6.5	16
142	Gene expression profiling in chronic inflammatory demyelinating polyneuropathy. Journal of Neuroimmunology, 2005, 159, 203-214.	2.3	43
143	The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. Journal of Neurology, 2005, 252, i19-i25.	3.6	72
144	A neuropsychological assessment of phobias in patients with stiff person syndrome. Neurology, 2005, 64, 1961-1963.	1.1	53

9

#	ARTICLE	IF	CITATIONS
145	Analysis of GAD65 Autoantibodies in Stiff-Person Syndrome Patients. Journal of Immunology, 2005, 175, 7755-7762.	0.8	133
146	Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain, 2005, 128, 1887-1896.	7.6	144
147	Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases. JAMA - Journal of the American Medical Association, 2004, 291, 2367.	7.4	263
148	Anti–Glutamic Acid Decarboxylase Antibodies in the Serum and Cerebrospinal Fluid of Patients With Stiff-Person Syndrome. Archives of Neurology, 2004, 61, 902.	4.5	110
149	Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity. Brain, 2004, 127, 1182-1190.	7.6	84
150	The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. , 2004, 102, 177-193.		189
151	Stiff-person syndrome. Current Treatment Options in Neurology, 2003, 5, 79-90.	1.8	73
152	Immunotherapy in autoimmune neuromuscular disorders. Lancet Neurology, The, 2003, 2, 22-32.	10.2	50
153	Expression of IFN-Î ³ -inducible chemokines in inclusion body myositis. Journal of Neuroimmunology, 2003, 141, 125-131.	2.3	69
154	Polymyositis and dermatomyositis. Lancet, The, 2003, 362, 971-982.	13.7	1,306
155			
	Basic Principles of Immunotherapy for Neurologic Diseases. Seminars in Neurology, 2003, 23, 121-132.	1.4	20
156	Basic Principles of Immunotherapy for Neurologic Diseases. Seminars in Neurology, 2003, 23, 121-132. Therapeutic Approaches in Patients with Inflammatory Myopathies. Seminars in Neurology, 2003, 23, 199-206.	1.4	20 47
156 157	 Basic Principles of Immunotherapy for Neurologic Diseases. Seminars in Neurology, 2003, 23, 121-132. Therapeutic Approaches in Patients with Inflammatory Myopathies. Seminars in Neurology, 2003, 23, 199-206. Strokes, thromboembolic events, and IVIg. Neurology, 2003, 60, 1736-1737. 	1.4 1.4 1.1	20 47 86
156 157 158	Basic Principles of Immunotherapy for Neurologic Diseases. Seminars in Neurology, 2003, 23, 121-132. Therapeutic Approaches in Patients with Inflammatory Myopathies. Seminars in Neurology, 2003, 23, 199-206. Strokes, thromboembolic events, and IVIg. Neurology, 2003, 60, 1736-1737. Blockade of blocking antibodies in Guillain-Barriz1/2 syndromes: ?Unblocking? the mystery of action of intravenous immunoglobulin. Annals of Neurology, 2002, 51, 667-669.	1.4 1.4 1.1 5.3	20 47 86 22
156 157 158 159	Basic Principles of Immunotherapy for Neurologic Diseases. Seminars in Neurology, 2003, 23, 121-132. Therapeutic Approaches in Patients with Inflammatory Myopathies. Seminars in Neurology, 2003, 23, 199-206. Strokes, thromboembolic events, and IVIg. Neurology, 2003, 60, 1736-1737. Blockade of blocking antibodies in Guillain-Barrig1/2 syndromes: ?Unblocking? the mystery of action of intravenous immunoglobulin. Annals of Neurology, 2002, 51, 667-669. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology, 2002, 59, S13-21.	1.4 1.4 1.1 5.3 1.1	20 47 86 22 139
156 157 158 159 160	Basic Principles of Immunotherapy for Neurologic Diseases. Seminars in Neurology, 2003, 23, 121-132. Therapeutic Approaches in Patients with Inflammatory Myopathies. Seminars in Neurology, 2003, 23, 199-206. Strokes, thromboembolic events, and IVIg. Neurology, 2003, 60, 1736-1737. Blockade of blocking antibodies in Guillain-Barriz 1/2 syndromes: ?Unblocking? the mystery of action of intravenous immunoglobulin. Annals of Neurology, 2002, 51, 667-669. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology, 2002, 59, S13-21. Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology, 2002, 59, S7-12.	1.4 1.4 1.1 5.3 1.1 1.1	20 47 86 22 139 73
156 157 158 159 160	Basic Principles of Immunotherapy for Neurologic Diseases. Seminars in Neurology, 2003, 23, 121-132. Therapeutic Approaches in Patients with Inflammatory Myopathies. Seminars in Neurology, 2003, 23, 199-206. Strokes, thromboembolic events, and IVIg. Neurology, 2003, 60, 1736-1737. Blockade of blocking antibodies in Guillain-Barriz ½ syndromes: ?Unblocking? the mystery of action of intravenous immunoglobulin. Annals of Neurology, 2002, 51, 667-669. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology, 2002, 59, S13-21. Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology, 2002, 59, S7-12. Peripheral neuropathy and antiretroviral drugs. Journal of the Peripheral Nervous System, 2001, 6, 14-20.	1.4 1.4 1.1 5.3 1.1 1.1 3.1	20 47 86 22 139 73 208

#	Article	IF	CITATIONS
163	High-Dose Intravenous Immune Globulin for Stiff-Person Syndrome. New England Journal of Medicine, 2001, 345, 1870-1876.	27.0	396
164	Motor cortex excitability in stiff-person syndrome. Brain, 2000, 123, 2231-2239.	7.6	117
165	Downregulation of TGF- $\hat{1}^21$ mRNA and Protein in the Muscles of Patients with Inflammatory Myopathies after Treatment with High-Dose Intravenous Immunoglobulin. Clinical Immunology, 2000, 94, 99-104.	3.2	111
166	Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines. Muscle and Nerve, 1999, 22, 1479-1497.	2.2	183
167	Expression of the Costimulatory Molecule BB-1, the Ligands CTLA-4 and CD28, and their mRNA in Inflammatory Myopathies. American Journal of Pathology, 1999, 155, 453-460.	3.8	111
168	The Stiff-Person Syndrome: An Autoimmune Disorder Affecting Neurotransmission of γ-Aminobutyric Acid. Annals of Internal Medicine, 1999, 131, 522.	3.9	176
169	Advances in chronic inflammatory demyelinating polyneuropathy: disease variants and inflammatory response mediators and modifiers. Current Opinion in Neurology, 1999, 12, 403-409.	3.6	48
170	Rimmed vacuoles with β-amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (postpoliomyelitis muscular atrophy): similarities with inclusion body myositis. Human Pathology, 1998, 29, 1128-1133.	2.0	51
171	Molecular Immunology and Genetics of Inflammatory Muscle Diseases. Archives of Neurology, 1998, 55, 1509.	4.5	107
172	A Study of the Interferon Antiviral Mechanism: Apoptosis Activation by the 2–5A System. Journal of Experimental Medicine, 1997, 186, 967-972.	8.5	256
173	Intravenous Immune Globulin Therapy for Neurologic Diseases. Annals of Internal Medicine, 1997, 126, 721.	3.9	204
174	Inclusion body myositis and paraproteinemia: Incidence and immunopathologic correlations. Annals of Neurology, 1997, 41, 100-104.	5.3	55
175	Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: Assessments based on controlled treatment trials in patients with neurological diseases. Muscle and Nerve, 1997, 20, 1102-1107.	2.2	66
176	Reply: Meningitis and Skin Reaction after Intravenous Immune Globulin Therapy. Annals of Internal Medicine, 1997, 127, 1130.	3.9	13
177	Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barré syndrome, myasthenia gravis and dermatomyositis. Journal of Neuroimmunology, 1996, 71, 227-229.	2.3	44
178	MHC Class l-Mediated Cytotoxicity Does Not Induce Apoptosis in Muscle Fibers nor in Inflammatory T Cells. Journal of Neuropathology and Experimental Neurology, 1996, 55, 1205-1209.	1.7	86
179	Autoimmune ataxic neuropathies (sensory ganglionopathies): Are glycolipids the responsible autoantigens?. Annals of Neurology, 1996, 39, 419-422.	5.3	73
180	A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology, 1996, 40, 792-795.	5.3	200

#	Article	IF	CITATIONS
181	Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain, 1996, 119, 1887-1893.	7.6	134
182	Common variable immunodeficiency and inclusion body myositis: A distinct myopathy mediated by natural killer cells. Annals of Neurology, 1995, 37, 806-810.	5.3	37
183	Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: Present and future prospects. Annals of Neurology, 1995, 37, 2-13.	5.3	67
184	Immunopathogenesis of inflammatory myopathies. Annals of Neurology, 1995, 37, 74-86.	5.3	195
185	Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides. Annals of Neurology, 1995, 38, 218-224.	5.3	166
186	Identification of macrophages in the muscle biopsy preparations: A comparative study using specific monoclonal antimacrophage antibodies and acid phosphatase reaction. Muscle and Nerve, 1995, 18, 242-244.	2.2	7
187	PolioRedux. The Sciences, 1995, 35, 30-35.	0.1	0
188	Role of the Muscle in Acute Poliomyelitis Infection. Annals of the New York Academy of Sciences, 1995, 753, 58-67.	3.8	10
189	Progression of Oral-Motor and Swallowing Symptoms in the Post-Polio Syndrome. Annals of the New York Academy of Sciences, 1995, 753, 87-95.	3.8	16
190	Pathogenetic Mechanisms of Post-Polio Syndrome: Morphological, Electrophysiological, Virological, and Immunological Correlations. Annals of the New York Academy of Sciences, 1995, 753, 167-185.	3.8	110
191	A Double-Blind, Placebo-Controlled, Trial of Amantadine for the Treatment, of Fatigue in Patients with the, Post-Polio Syndrome. Annals of the New York Academy of Sciences, 1995, 753, 296-302.	3.8	53
192	A Double-Blind, Placebo-Controlled Trial of High-Dose Prednisone for the Treatment of Post-Poliomyelitis Syndrome. Annals of the New York Academy of Sciences, 1995, 753, 303-313.	3.8	42
193	How To Design a Therapeutic Study in Patients with the Post-Polio Syndrome Annals of the New York Academy of Sciences, 1995, 753, 314-320.	3.8	5
194	Concluding Remarks and Future Strategies. Annals of the New York Academy of Sciences, 1995, 753, 366-369.	3.8	0
195	Aseptic Meningitis and Intravenous Immunoglobulin Therapy. Annals of Internal Medicine, 1995, 122, 316.	3.9	8
196	Neuroimmunotherapy: A Practical Approach to the Treatment of Immune-Mediated Neurologic Diseases. Seminars in Neurology, 1994, 14, 97-105.	1.4	10
197	Polymyositis inpatients infected with human T-cell leukemia virus type I: The role of the virus in the cause of the disease. Annals of Neurology, 1994, 36, 643-649.	5.3	75
198	Current treatment of the inflammatory myopathies. Current Opinion in Rheumatology, 1994, 6, 595-602.	4.3	50

#	Article	IF	CITATIONS
199	Search for HIV proviral DNA and amplified sequences in the muscle biopsies of patients with HIV polymyositis. Muscle and Nerve, 1993, 16, 408-413.	2.2	48
200	A Controlled Trial of High-Dose Intravenous Immune Globulin Infusions as Treatment for Dermatomyositis. New England Journal of Medicine, 1993, 329, 1993-2000.	27.0	1,024
201	Controlled Trial of Plasma Exchange and Leukapheresis in Polymyositis and Dermatomyositis. New England Journal of Medicine, 1992, 326, 1380-1384.	27.0	320
202	Antibodies to acidic glycolipids in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. Journal of the Neurological Sciences, 1992, 107, 111-121.	0.6	161
203	Sensory neuropathy associated with monoclonal immunoglobulin M to GD1b ganglioside. Annals of Neurology, 1992, 31, 683-685.	5.3	93
204	Polymyositis, Dermatomyositis, and Inclusion-Body Myositis. New England Journal of Medicine, 1991, 325, 1487-1498.	27.0	844
205	Immunocytochemical and virological characteristics of hiv-associated inflammatory myopathies: Similarities with seronegative polymyositis. Annals of Neurology, 1991, 29, 474-481.	5.3	144
206	Dysphagia in Patients with the Post-Polio Syndrome. New England Journal of Medicine, 1991, 324, 1162-1167.	27.0	96
207	A New Approach to the Classification of Idiopathic Inflammatory Myopathy. Medicine (United States), 1991, 70, 360-374.	1.0	889
208	Mitochondrial Myopathy Caused by Long-Term Zidovudine Therapy. New England Journal of Medicine, 1990, 322, 1098-1105.	27.0	849
209	Neuromuscular diseases associated with human immunodeficiency virus infection. Annals of Neurology, 1988, 23, S38-S48.	5.3	236
210	Demyelination induced by intraneural injection of human antimyelin-associated glycoprotein antibodies. Muscle and Nerve, 1988, 11, 1169-1176.	2.2	134
211	Chronic idiopathic ataxic neuropathy. Annals of Neurology, 1986, 19, 545-554.	5.3	136
212	A Long-Term Follow-up Study of Patients with Post-Poliomyelitis Neuromuscular Symptoms. New England Journal of Medicine, 1986, 314, 959-963.	27.0	350
213	Polymyositis Associated With AIDS Retrovirus. JAMA - Journal of the American Medical Association, 1986, 256, 2381.	7.4	193
214	Monoclonal IgM in a patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groups. Annals of Neurology, 1985, 18, 655-659.	5.3	183
215	Tremor as a Feature of Chronic Relapsing and Dysgammaglobulinemic Polyneuropathies. Archives of Neurology, 1984, 41, 711.	4.5	91
216	Treatment of ?permanent? muscle weakness in familial hypokalemic periodic paralysis. Muscle and Nerve, 1983, 6, 182-186.	2.2	55

#	Article	IF	CITATIONS
217	Chronic relapsing (Dysimmune) polyneuropathy: Pathogenesis and treatment. Annals of Neurology, 1981, 9, 134-145.	5.3	280
218	Treatment for inclusion body myositis. The Cochrane Library, 0, , .	2.8	11
219	Enteroviruses and Human Neuromuscular Diseases. , 0, , 387-398.		16